Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of Dactinomycin as Salvage Therapy in Patients With Persistent or Recurrent Low-Risk Gestational Trophoblastic Neoplasia

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Completed	12 to 50	NCI	GOG-176 NCT00003688, GOG-0176

Trial Description

Purpose:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Phase II trial to study the effectiveness of dactinomycin in treating patients who have persistent or recurrent gestational trophoblastic neoplasia.

Eligibility:

• 12-50 years old
• No metastatic cancer other than lung or vagina
• At least 1 week since chemotherapy
• No previous chemotherapy drugs other than methotrexate
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive an infusion of dactinomycin once every 2 weeks for as long as benefit is shown. Patients will be evaluated every 2 weeks for 2 months and once a month for 10 months.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Gynecologic Oncology Group

Allan Covens, MD, Protocol chair		Ph: 416-480-4026 Email: al.covens@sunnybrook.ca

Registry Information
Official Title		Pulse Actinomycin-D as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Neoplasia
Trial Start Date		1999-10-18
Registered in ClinicalTrials.gov		NCT00003688
Date Submitted to PDQ		1998-12-10
Information Last Verified		2003-12-10
NCI Grant/Contract Number		CA27469

Back to Top